Autolus TherapeuticsNASDAQ: AUTL

The majority of patients that responded to obe-cel showed durable responses with the potential for a long-term plateau of survival outcomes 40% patients are in ongoing remission without subsequent stem cell transplant (SCT) or other intervention Ongoing CAR T persistence was associated with improved event-free survival Autolus will host a conference call and webcast to discuss the presented data on Saturday June 1, 2024 at 9:30 am EDT/8:30 am CDT/2:30 pm BST (details below) LONDON, May 31, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces longer-term follow-up and additional data analysis from the pivotal Phase 1b/2 FELIX study of obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL), being presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, (May 31 – June 4, 2024, Chicago). “At 21 months of median follow up, we're really pleased to be observing the potential for a long-term plateau of survival outcomes with obe-cel in the FELIX trial,” said Dr. Christian Itin, Chief Executive Officer of Autolus.

Autolus Therapeutics plc will be presenting additional analyses from the FELIX Phase 2 data at upcoming conferences, with two patients enrolled in the Phase 1 SLE trial. The company is on track to release initial data by the end of 2024. The European Medicines Agency has accepted the Market Authorization Application for obe-cel in r/r adult ALL. A conference call will be held today at 08:30 am EDT/13:30 pm BST, and participants should pre-register using the link provided in the press release. Autolus CEO, Dr. Christian Itin, stated that the company is actively engaging with the FDA in the regulatory review process for obe-cel and preparing for commercial readiness activities.

Autolus Therapeutics plc (NASDAQ:AUTL) is holding a conference call on May 17, 2024 at 8:30 AM ET to discuss its Q1 2024 earnings and business updates. The call will be led by CEO Christian Itin and CFO Rob Dolski, with investor relations represented by Olivia Manser. Various analysts from firms such as Jefferies, Deutsche Bank, and Needham & Company will also be participating in the call. The call is being recorded for reference.

Autolus Therapeutics PLC Sponsored ADR (AUTL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Obe-cel continues to demonstrate comparative efficacy with fewer side effects to approved therapies. Thus, the company will likely gain its first market authorization in November. Autolus made several strong leadership hires with direct experience in M&A, oncology, and lupus, a new research area.

Autolus Therapeutics is developing cell-based immunotherapy for cancer, focusing on CD19 in ALL. Their flagship product, obe-cel, has shown promising results in treating relapsed/refractory B-cell ALL with reduced toxicities compared to other CAR T-cell therapies. Autolus Therapeutics also has a dual-targeted BCMA/CD19 CAR T-cell therapy called AUTO8, which has shown positive responses in patients with relapsed/refractory multiple myeloma.

Autolus Therapeutics plc (NASDAQ:AUTL ) Q3 2023 Earnings Conference Call November 2, 2023 9:00 AM ET Company Participants Julia Wilson – Investor Relations Christian Itin – Chief Executive Officer Rob Dolski – Chief Financial Officer Conference Call Participants Matthew Phipps – William Blair Dev Prasad – Jefferies Gil Blum – Needham and Company Yanan Zhu – Wells Fargo Karina Rabayeva – Truist Simon Baker – Redburn Atlantic Operator Hello, ladies and gentlemen, and welcome to the Autolus Therapeutics Third Quarter 2023 Financial Results Conference Call and Business Update. At this time, all participants are in listen-only mode.

LONDON, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2023 financial results and operational highlights before open of US markets on Thursday, November 2, 2023. Management will host a conference call and webcast at 9:00 am ET/1:00 pm GMT to discuss the company's financial results and provide a general business update.

Autolus Therapeutics plc (NASDAQ:AUTL ) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Dr. Christian Itin - CEO Dr. Lucinda Crabtree - CFO Rob Dolski - incoming CFO Julia Wilson - IR Conference Call Participants Matt Phipps - William Blair Asthika Goonewardene - Truist Financial Kelly Shi - Jefferies Noah Burhance - J.P. Morgan Operator Hello, ladies and gentlemen, and welcome to the Autolus Therapeutics Second Quarter 2023 Financial Results Conference.